Literature DB >> 21219084

A simple method to increase the transduction efficiency of single-stranded adeno-associated virus vectors in vitro and in vivo.

Wenqin Ma1, Baozheng Li, Chen Ling, Giridhara R Jayandharan, Arun Srivastava, Barry J Byrne.   

Abstract

We have recently shown that co-administration of conventional single-stranded adeno-associated virus 2 (ssAAV2) vectors with self-complementary (sc) AAV2-protein phosphatase 5 (PP5) vectors leads to a significant increase in the transduction efficiency of ssAAV2 vectors in human cells in vitro as well as in murine hepatocytes in vivo. In the present study, this strategy has been further optimized by generating a mixed population of ssAAV2-EGFP and scAAV2-PP5 vectors at a 10:1 ratio to achieve enhanced green fluorescent protein (EGFP) transgene expression at approximately 5- to 10-fold higher efficiency, both in vitro and in vivo. This simple coproduction method should be adaptable to any ssAAV serotype vector containing transgene cassettes that are too large to be encapsidated in scAAV vectors.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21219084      PMCID: PMC3081437          DOI: 10.1089/hum.2010.243

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  38 in total

1.  Gene therapy. Viral vectors still pack surprises.

Authors:  E Marshall
Journal:  Science       Date:  2001-11-23       Impact factor: 47.728

Review 2.  Use of adeno-associated virus as a general transduction vector for mammalian cells.

Authors:  N Muzyczka
Journal:  Curr Top Microbiol Immunol       Date:  1992       Impact factor: 4.291

Review 3.  Recombinant adeno-associated virus vectors for gene therapy.

Authors:  Thomas J Conlon; Terence R Flotte
Journal:  Expert Opin Biol Ther       Date:  2004-07       Impact factor: 4.388

4.  Self-complementary adeno-associated virus 2 (AAV)-T cell protein tyrosine phosphatase vectors as helper viruses to improve transduction efficiency of conventional single-stranded AAV vectors in vitro and in vivo.

Authors:  Li Zhong; Linyuan Chen; Yanjun Li; Keyun Qing; Kirsten A Weigel-Kelley; Rebecca J Chan; Mervin C Yoder; Arun Srivastava
Journal:  Mol Ther       Date:  2004-11       Impact factor: 11.454

5.  A single adeno-associated virus (AAV)-murine factor VIII vector partially corrects the hemophilia A phenotype.

Authors:  R Sarkar; W Xiao; H H Kazazian
Journal:  J Thromb Haemost       Date:  2003-02       Impact factor: 5.824

6.  AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B.

Authors:  Catherine S Manno; Amy J Chew; Sylvia Hutchison; Peter J Larson; Roland W Herzog; Valder R Arruda; Shing Jen Tai; Margaret V Ragni; Arthur Thompson; Margareth Ozelo; Linda B Couto; Debra G B Leonard; Frederick A Johnson; Alan McClelland; Ciaran Scallan; Erik Skarsgard; Alan W Flake; Mark A Kay; Katherine A High; Bertil Glader
Journal:  Blood       Date:  2002-12-19       Impact factor: 22.113

7.  Phase I trial of intramuscular injection of a recombinant adeno-associated virus alpha 1-antitrypsin (rAAV2-CB-hAAT) gene vector to AAT-deficient adults.

Authors:  Terence R Flotte; Mark L Brantly; L Terry Spencer; Barry J Byrne; Carolyn T Spencer; Dawn J Baker; Margaret Humphries
Journal:  Hum Gene Ther       Date:  2004-01       Impact factor: 5.695

8.  Rapid and highly efficient transduction by double-stranded adeno-associated virus vectors in vitro and in vivo.

Authors:  Z Wang; H-I Ma; J Li; L Sun; J Zhang; X Xiao
Journal:  Gene Ther       Date:  2003-12       Impact factor: 5.250

9.  Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy.

Authors:  Guang-Ping Gao; Mauricio R Alvira; Lili Wang; Roberto Calcedo; Julie Johnston; James M Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-21       Impact factor: 11.205

10.  Improved transduction of primary murine hepatocytes by recombinant adeno-associated virus 2 vectors in vivo.

Authors:  L Zhong; W Li; Z Yang; L Chen; Y Li; K Qing; K A Weigel-Kelley; M C Yoder; W Shou; A Srivastava
Journal:  Gene Ther       Date:  2004-07       Impact factor: 5.250

View more
  5 in total

1.  Enhanced Transduction of Human Hematopoietic Stem Cells by AAV6 Vectors: Implications in Gene Therapy and Genome Editing.

Authors:  Hua Yang; Keyun Qing; Geoffrey D Keeler; Ling Yin; Mario Mietzsch; Chen Ling; Brad E Hoffman; Mavis Agbandje-McKenna; Mengqun Tan; Wei Wang; Arun Srivastava
Journal:  Mol Ther Nucleic Acids       Date:  2020-03-29       Impact factor: 8.886

2.  Analysis of transduction efficiency, tropism and axonal transport of AAV serotypes 1, 2, 5, 6, 8 and 9 in the mouse brain.

Authors:  Dominik F Aschauer; Sebastian Kreuz; Simon Rumpel
Journal:  PLoS One       Date:  2013-09-27       Impact factor: 3.240

Review 3.  Progresses towards safe and efficient gene therapy vectors.

Authors:  Sergiu Chira; Carlo S Jackson; Iulian Oprea; Ferhat Ozturk; Michael S Pepper; Iulia Diaconu; Cornelia Braicu; Lajos-Zsolt Raduly; George A Calin; Ioana Berindan-Neagoe
Journal:  Oncotarget       Date:  2015-10-13

4.  High-Efficiency Transduction of Primary Human Hematopoietic Stem/Progenitor Cells by AAV6 Vectors: Strategies for Overcoming Donor-Variation and Implications in Genome Editing.

Authors:  Chen Ling; Kanit Bhukhai; Zifei Yin; Mengqun Tan; Mervin C Yoder; Philippe Leboulch; Emmanuel Payen; Arun Srivastava
Journal:  Sci Rep       Date:  2016-10-19       Impact factor: 4.379

5.  Liposome Lipid-Based Formulation Has the Least Influence on rAAV Transduction Compared to Other Transfection Agents.

Authors:  Pengpeng Guo; Chenghui Yu; Qingxin Wang; Ruirong Zhang; Xianze Meng; Yinglu Feng
Journal:  Mol Ther Methods Clin Dev       Date:  2018-04-12       Impact factor: 6.698

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.